top of page
Capture d’écran, le 2021-06-07 à 08.25

EMERGENCY USE AUTHORIZATION (EUA) OF THE JANSSEN COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER : https://www.fda.gov

 

EMERGENCY USE AUTHORIZATION (EUA) OFTHE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) :
https://www.fda.gov

 

FACT SHEET FOR RECIPIENTS AND CAREGIVERSEMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER :
https://www.fda.gov

 

Données COVID-19 par âge et sexe au Québec
https://www.inspq.qc.ca

Benefits of Getting a COVID-19 Vaccine

https://www.cdc.gov

 

he Vaccine Adverse Event Reporting System (VAERS)
https://wonder.cdc.gov

 

Maladie à coronavirus (COVID-19) : Prévention et risques
https://www.canada.ca/fr/sante-publique

Le consentement : Guide à l'intention des médecins du Canada

https://www.cmpa-acpm.ca

 

Fiche de synthèse : différentes technologies vaccinales anti-covid

https://reinfocovid.fr

 

8 - L'article 21 du Code civil du Québec et la recherche : présent et futur
https://www.acfas.ca

 

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
https://clinicaltrials.gov

RÉFÉRENCES

Ancre 1
bottom of page